A class action lawsuit has been filed against Beta Bionics for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly found serious safety issues with the device, including dangerous insulin dosing causing hypoglycemia, which Beta Bionics failed to adequately address. Investors who bought Beta Bionics stock between July 30, 2025, and February 24, 2026, may be eligible for compensation. Interested parties can join the lawsuit or seek lead plaintiff status by November 3, 2026.
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...
EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...
Lakeland Industries continues to face profitability challenges with a projected negative EPS of -$0.06 and recent unprofitability. However, the company secured important contracts with the Hong Kong Government Flying Service and Airports of Thailand,...
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
